Ospemifene

CAS No. 128607-22-7

Ospemifene( FC-1271a )

Catalog No. M11168 CAS No. 128607-22-7

Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 41 In Stock
25MG 55 In Stock
100MG 81 In Stock
200MG 122 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ospemifene
  • Note
    Research use only, not for human use.
  • Brief Description
    Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.
  • Description
    Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    FC-1271a
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER
  • Research Area
    Endocrinology
  • Indication
    ——

Chemical Information

  • CAS Number
    128607-22-7
  • Formula Weight
    378.89
  • Molecular Formula
    C24H23ClO2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 71 mg/mL warmed (187.38 mM); DMSO: 75 mg/mL (197.94 mM)
  • SMILES
    ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCO)C=C2)\C3=CC=CC=C3
  • Chemical Name
    2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Constantine GD, Kagan R, Miller PD.Menopause. 2016 Mar 29. [Epub ahead of print]
molnova catalog
related products
  • GDC-0927 racemate

    GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.

  • Methyl Isoferulate

    This product is isolated and purified from the leaves of Phyllostachys heterocycla.

  • 5Beta-Pregnane-3Alph...

    An inactive metabolite of progesterone by reduction at C5, C3, and C20 position.